FRANKLIN, Mass., March 14, 2017 /PRNewswire/ -- Arthrosurface, Inc. announced today they will be highlighting the OVO™Primary Stemless Shoulder system along with recent data published supporting their proprietary inlay glenoid shoulder product at the 2017 AAOS conference in San Diego, CA March 15-18 at
Stemless implants were originally used for young patient with osteoarthritis and minimal bone deformity. The uses have expanded to all age groups with a wide range of pathologies with excellent results. It can be used in all patients in lieu of a standard total shoulder arthroplasty with the advantages of being bone preserving, anatomical, and in appropriately selected patients, able to do as a short stay or same day procedure.
"The OVO Primary Stemless Shoulder system is an excellent choice for the patient who suffers from osteoarthritis of the glenohumeral joint and who desires to maintain an active lifestyle post-surgical intervention," said Joe Darling, Executive Chairman of Arthrosurface. "In a traditional stemmed implant design, there are lifelong restrictions placed on the patient post-surgery; limits on the amount of weight that can be lifted and certain activities such as yoga are no longer permitted. This is due to the amount of healthy bone that must be removed to allow a long titanium stem to be placed deep inside the humeral canal. In a stemless implant the amount of bone removal is far less than a stemmed system, related complications are avoided, and minimal lifestyle restrictions are placed on the patient following postoperative recovery and rehabilitation."
The Arthrosurface OVO™ Primary Stemless Shoulder system is the only system on the market today that offers a non-spherical humeral head which matches the native anatomy more closely than circular head designs offered by the other stemmed and stemless arthroplasty systems. Independent studies have shown that a non-spherical head optimizes the natural movement of the shoulder.
In addition, Arthrosurface is the only system which offers an inlay glenoid. Glenoid loosening is a significant concern post-surgery and has been attributed to the interaction of the humeral head implant against the outer edges of an onlay glenoid implants, creating a "rocking horse" effect. Recent published data reported no loosening of the Arthrosurface inlay glenoid after 4,000 cycles, whereas all onlay designs tested were clinically loose after approximately 1100 cycles.
The inherent advantages of the OVO Primary Stemless Shoulder system resonate with clinicians which is reflected in double-digit growth rates annually since the market introduction in 2009. The inlay glenoid is expected to be commercially available in Europe later this year.
Arthrosurface, Inc. is a global orthopedic medical technology business providing a broad portfolio of essential products and instrumentation used to treat upper and lower extremity orthopedic conditions caused by trauma, injury and arthritic disease. The product offerings include devices, instruments and biologics designed to preserve and restore the joints so patients can maintain an active lifestyle. The Company offers a variety of unique systems that provide less invasive technologies for surgeons that can be used to treat a wide range of joint conditions. Founded in 2002, Arthrosurface markets and distributes its products in the US and around the world and has succeeded in helping patients return to activity for over 13 years. For more information, please go to our website at www.Arthrosurface.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-arthrosurface-ovo---a-primary-stemless-total-shoulder-system-300423752.html
SOURCE Arthrosurface, Inc.
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All